Leading science and technology firm Merck may open a pilot facility for bioproduction in India if the ecosystem in the country is predictable, a top company official said.
"Given the demand for biosimilars in India and the intent to implement world-class regulations for biosimilars, Merck would seriously look into setting up a pilot facility for bioproduction in India," Merck Member of the Executive Board and Life Science CEO Udit Batra told PTI.
This would replicate the centres that already exist in Martillac in France and two additional ones that Merck has recently announced to be opened in Shanghai and Greater Boston, he added.
Also Read
A bioproduction centre provides a range of process development capablities and services.
"The investment on opening a centre is between USD 30 and 50 million," Batra said.
The plant in India if opened, would produce the first batches of non clinical materials for biosimilars, he added.
"For Merck Life science, India is one of the top five markets globally and we have around 2,500 employees in India," Batra said.
Merck Life science has a Merck Lab in India and has production facilities in Goa and Bengaluru, he added.
Founded in 1668, Merck is a leading science and technology in healthcare, life science and performance materials. It currently has around 50,000 employees globally.
Disclaimer: No Business Standard Journalist was involved in creation of this content
